New pneumococcal conjugate vaccines (PCVs), 15-and 20-valent (PCV15 and PCV20),
have been licensed for use among US adults based on safety and immunogenicity data …

The incidence of invasive pneumococcal disease (IPD) caused by infection with the
pathogen Streptococcus pneumoniae (Spn) has been on a downward trend for decades due …

Abstract Background Pneumococcal conjugate vaccines (PCVs) have greatly reduced the
incidence of pneumococcal disease, yet unmet medical need remains due to increased …

Characterizing the genetic diversity of pathogens within the host promises to greatly improve
surveillance and reconstruction of transmission chains. For bacteria, it also informs our …

Background: Pneumococcal disease remains a public health priority in adults. Safety and
immunogenicity of 2 different formulations of 15-valent pneumococcal conjugate vaccine …

The introduction of pneumococcal conjugate vaccines (PCVs) 7 and 13 into national
childhood immunization programs in the US in 2000 and 2010, respectively, proved to be …

Background Ontario, Canada introduced a publicly-funded 13-valent pneumococcal
conjugate vaccine (PCV13) for infants in 2010, replacing the 10-valent (PCV10, 2009–2010) …

Background The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed based
on the results of immunogenicity studies and correlates of protection derived from …

Background Limited information is available on pneumococcal colonization among adults.
We studied pneumococcal carriage dynamics in healthy adults using high-sensitivity …

Despite use of 7-valent pneumococcal conjugate vaccine, incidence of pleural effusion and
empyema (pediatric complicated pneumococcal pneumonia [PCPP]) is reportedly …